Overview
Cetya Therapeutics, Inc. (“Cetya”) is a Delaware C-Corporation formed in 2012 to commercialize histone deacetylase inhibitors (HDACi) based on largazole. More than 30 largazole analogs have been synthesized, some with best-in-class profiles as HDACi including:
- Biochemical and cell-based potency
- Upregulation of fetal hemoglobin expression
- In-vivo anti-cancer activity
As a drug class, HDACis are effective in treating certain cancers, and thought leaders in epigenetics believe that this class of compounds may have broader application in treating other conditions such as:
- Hemoglobinopathies
- Immuno-oncology
- Chronic inflammation
- Neurological disorders
- Fibrotic diseases
Cetya has chosen to focus on hemoglobinopathies, specifically sickle cell disease (SCD) as its lead clinical indication.
Intellectual Property
Cetya holds exclusive worldwide license rights to the largazole analog intellectual property created by Dr. Robert M. Williams at Colorado State University. This estate consists of five issued US patents, three issued international patents, two pending international patent applications and one PCT patent application. The patents contain composition of matter claims on our compounds, field of use claims in hemoglobinopathies and oncology, and method claims on our novel manufacturing process.